Interviews

Jordan Karlitz, MD, highlights racial, ethnic, and socioeconomic disparities in rising CRC mortality rates among younger adults, driven by gaps in screening and awareness.

A new study links telomere length genetics to IPF risk, showing how rare variants and polygenic scores may guide future screening and precision care.

Sarah M. Lima, PhD, MPH, on how historical redlining continues to shape breast cancer survival disparities through treatment access and innovation.

Study finds breast cancer survival gaps tied to historical redlining narrowed over time, though newer therapies may be widening disparities again.

Jordan Karlitz, MD, explains the rise in CRC-related deaths in younger adults, stressing the need for earlier screening and symptom awareness.

Kavita Nair, PhD, discusses integrating neurology and pharmacy services to improve MS care coordination and reduce treatment delays.

New stroke breakthroughs spotlight faster treatment, factor XI prevention, better recovery, and the push to deliver care equitably with smart wearables.

Nicholas Richardson, DO, at Precision for Medicine, breaks down minimal residual disease and MRD negativity as FDA end points for faster myeloma approvals.

Vishal A. Patel, MD, shares skin cancer prevention tips, highlighting sun-smart habits, risk-based screening, and at-home early detection.

As more oral cancer therapies become available, medically integrated dispensing models are increasingly vital, says Kenneth Komorny, PharmD, BCPS.

OCEANIC-STROKE trial data show asundexian cuts ischemic stroke across subtypes with no rise in major bleeding, which could reshape antithrombotic choices.

The Orphan Drug Act has boosted treatments, but Kristi Martin, MPA, MA, urges modernizing incentives and pricing to sustain future innovation.

Susan Vadaparampil, PhD, MPH, explains that aligning clinical trials with community needs can improve enrollment diversity.

Ameet Patel, MD, discusses scaling CAR T-cell therapy and bispecific therapies to improve access and potentially cure multiple myeloma.

Vishal A. Patel, MD, explains that delayed skin cancer diagnoses contribute to more advanced disease and poorer outcomes in patients with darker skin.

Medically integrated dispensing (MID) models help build patient trust in pharmacists, which can help improve adherence, explains Kenneth Komorny, PharmD, BCPS.

Patient navigators, community health workers, and/or peer advocates serve as trusted community resources for patients, Susan Vadaparampil, PhD, MPH, says.

Medically integrated dispensing is well-positioned to support value-based oncology care models and closer patient follow-up and monitoring, says Katherine Tobon, PharmD, BCOP.

Ashkan Shoamanesh, MD, discusses a secondary analysis of the efficacy and safety of the factor XIa inhibitor asundexian by underlying stroke etiology.

MID in oncology also enhances treatment adherence and improves patient outcomes, according to Kenneth Komorny, PharmD, BCPS.

Medically integrated dispensing (MID) improves monitoring and supports value-based care, but startup costs and payer barriers remain, notes Katherine Tobon, PharmD, BCOP.

Susan Vadaparampil, PhD, MPH, highlights disparities in cancer outcomes and trial enrollment but underscores that linking community screening programs with cancer centers may help.

Stroke patients face unequal access to clot-removal care; race and insurance shape transfers, even with Medicare—here’s what must change, according to Luke Messac, MD, PhD.

ED dizziness visits see rising MRI use at discharge; exam-guided imaging helps detect missed strokes and informs secondary prevention.

Stroke recovery improves when care addresses social needs like reducing loneliness and depression and strengthening support.

Targeted therapies, bispecifics, and CAR T-cell therapies are giving patients with multiple myeloma hope for long-term remission or a potential cure.

Linda Stein Gold, MD, shares insights on new therapeutic options for patients with various psoriasis subtypes and psoriatic arthritis.

City St. George’s researchers identified 9 genetic signatures and epigenetic changes driving lapatinib resistance in HER2-positive breast cancer.